|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Azilsartan kamedoxomil#Adult Indications and Dosage]] |
| {{Azilsartan}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Indications and Usage==
| |
| | |
| Edarbi is an angiotensin II receptor blocker (ARB) indicated for the treatment of [[hypertension]] to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and [[myocardial infarction]]s. These benefits have been seen in controlled trials of [[antihypertensive drugs]] from a wide variety of pharmacologic classes, including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Edarbi.
| |
| | |
| Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).
| |
| | |
| Numerous [[antihypertensive drugs]], from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in [[myocardial infarction]] and cardiovascular mortality also have been seen regularly.
| |
| | |
| Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe [[hypertension]] can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their [[hypertension]] (for example, patients with diabetes or [[hyperlipidemia]]), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.
| |
| | |
| Some [[antihypertensive drugs]] have smaller blood pressure effects (as monotherapy) in black patients, and many [[antihypertensive drugs]] have additional approved indications and effects (e.g., on [[angina]], [[heart failure]], or diabetic kidney disease). These considerations may guide selection of therapy.
| |
| | |
| Edarbi may be used alone or in combination with other [[antihypertensive agents]].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = EDARBI (AZILSARTAN KAMEDOXOMIL) TABLET [TAKEDA PHARMACEUTICALS AMERICA, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=75b16bfc-38c1-4133-bd7d-13258d54edec | publisher = | date = | accessdate = 19 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| [[Category:Angiotensin II receptor antagonists]]
| |
| [[Category:Benzimidazoles]]
| |
| [[Category:Carbamates]]
| |
| [[Category:Ethers]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |